By the Oral Pathology 360 Editorial Team
Rediscover the OP360 Archives | Revisiting diagnostic concepts, molecular discoveries and emerging treatment approaches through three expert lectures.
Ameloblastoma presents an enduring paradox in oral and maxillofacial pathology. Although classified as a benign odontogenic tumour, its locally aggressive behaviour can lead to extensive destruction of the jaws. Treatment may require substantial surgical resection, with consequences for facial appearance, oral function and quality of life.
For decades, the principal challenge has been achieving adequate disease control while minimising the morbidity associated with treatment.
But our understanding of ameloblastoma has been changing. Advances in molecular pathology have revealed genetic alterations and signalling pathways involved in tumour development, raising an important question:
Could understanding the biology of ameloblastoma help us treat it differently?
In this first edition of Rediscover the OP360 Archives, we revisit three Oral Pathology 360 presentations, spanning 2020 to 2024, that explore this evolving relationship between tumour biology, diagnosis and treatment.
1. Understanding Ameloblastoma: The Diagnostic and Biological Foundations
Ameloblastoma Current Concepts | October 2020
Ameloblastoma is familiar to most oral pathologists, yet its biological behaviour and management continue to generate discussion.
This presentation examines the evolution of our understanding of ameloblastoma, from its proposed origins and histopathological patterns to molecular alterations and treatment strategies.
The lecture explores the diverse molecular mechanisms implicated in tumour growth, invasion and recurrence, including the MAPK and Sonic Hedgehog signalling pathways. It also examines the growing recognition of BRAF mutations and their potential relevance to treatment.
Alongside these molecular developments, the presentation revisits the importance of conventional histopathology, imaging and the distinction between different forms of ameloblastoma.
An important message emerges: ameloblastoma cannot be understood through morphology alone, but neither can molecular findings be interpreted independently of the clinical and histopathological picture.
Watch the lecture: Ameloblastoma Current Concepts
2. Beyond the Scalpel: Exploring Alternatives to Extensive Surgery
Beyond the Scalpel: Unveiling the Future of Ameloblastoma Treatment | February 2024
Four years later, another OP360 presentation approached ameloblastoma from a different perspective.
If extensive surgery can cause significant morbidity, could molecular discoveries eventually offer less invasive treatment options?
The speaker explores the historical development of ameloblastoma management, the limitations of established treatment approaches, and the emergence of molecularly targeted therapies.
Particularly interesting is the discussion of neurotrophins and neurotrophin receptors, drawing on the speaker’s own research into signalling mechanisms in ameloblastoma.
These investigations raise questions about the biological differences between tumours and the possibility that different molecular pathways may influence their response to treatment.
The lecture also offers a personal perspective on scientific research: how an interest sparked during postgraduate training developed into years of investigation into ameloblastoma biology.
It reminds us that important advances often begin with a simple question about something we encounter routinely.
While the possibility of non-surgical treatment is compelling, much of the pathway-based research discussed remains exploratory. Identifying a molecular target does not, by itself, establish an effective therapy.
Watch the lecture: Beyond the Scalpel
3. Targeted Therapies: What Does the Clinical Evidence Tell Us?
Targeted Therapies in Ameloblastomas and Ameloblastic Carcinoma | Journal Club with Authors, November 2024
The third presentation brings the discussion from biological possibilities to published clinical evidence.
In this interactive Journal Club with Authors, the research team discusses a systematic review evaluating targeted therapies in odontogenic tumours.
The review identified 15 publications reporting 17 treated cases, predominantly ameloblastomas, with two cases of ameloblastic carcinoma.
The discussion focuses on molecular alterations, including BRAF and other potentially targetable mutations, the therapeutic agents used, treatment responses and reported adverse effects.
Several cases demonstrated reductions in tumour size, suggesting a potential role for targeted therapy in selected patients, particularly when extensive surgery would carry significant morbidity.
However, the authors also emphasised important limitations.
The available evidence was based on a small number of reported cases, with variable treatment approaches and limited follow-up. Although promising responses had been documented, these findings could not establish the long-term effectiveness or safety of targeted therapy as a replacement for surgery.
An especially important point emerged during the discussion: the immediate value of targeted therapies may lie in reducing tumour burden before surgery or providing options in selected recurrent, advanced or difficult-to-resect cases.
Watch the Journal Club with Authors
An Interesting Question from Our Learning Community
is there any correlation between the histological pattern and the kind of mutation present?”
Audience question · Journal Club with Authors, November 2024
It is an excellent question because it connects two increasingly important aspects of diagnostic pathology: what we observe microscopically and what we understand about the molecular mechanisms driving the tumour.
The speakers discussed why histological patterns do not necessarily predict specific mutations and why molecular profiling may provide additional information beyond conventional morphology.
This question also illustrates something valuable about our educational community: the discussions generated by these lectures often extend well beyond the original presentation.
The questions asked by our viewers are themselves worth revisiting.
Where Are We Today?
Since these presentations were delivered, further research has strengthened the evidence that molecularly targeted therapies can produce meaningful responses in selected patients with ameloblastoma.
A prospective observational study published in June 2026 reported radiological tumour regression in 10 of 11 patients receiving molecularly matched therapy. Four patients subsequently underwent surgery, with treatment allowing a reduction in the extent of resection.
A separate 2026 systematic review and meta-analysis involving 2,034 patients estimated the prevalence of the BRAF V600E mutation at approximately 72%, while its analysis of targeted treatment outcomes remained limited to 21 patients.
These findings are encouraging, particularly for a tumour where reducing treatment-related morbidity could have substantial benefits.
Nevertheless, significant questions remain regarding patient selection, treatment duration, resistance, adverse effects, recurrence and long-term disease control.
Molecularly targeted therapy is a promising development, but it is not yet a universal alternative to surgery. Management must continue to be individualised, with appropriate multidisciplinary assessment.
Revisiting the Past, Understanding the Present
Viewed together, these three presentations offer more than a review of ameloblastoma.
They illustrate how scientific understanding develops: from recognising histopathological and biological features, to investigating molecular pathways, to examining whether those discoveries can improve treatment.
They also remind us that advances in diagnosis and treatment are rarely isolated achievements. They emerge through continuing research, collaboration and critical discussion.
The question is no longer simply whether ameloblastoma has identifiable molecular targets, but how we can translate that knowledge into safe, effective and less morbid treatment.
We invite you to revisit these lectures, explore the discussions and share your own perspectives.
What do you think will be the most important development in ameloblastoma management over the coming decade?
Sources for the 2026 update
- Targetable alterations and personalized treatment in ameloblastoma — npj Precision Oncology, June 2026. Open access. Nature
- Precision therapy for BRAF V600E-mutated ameloblastoma: Systematic review insights — July 2026. PubMed
Rediscover the OP360 Archives is an educational series from Oral Pathology 360, bringing together selected presentations from our freely accessible video archive around important clinical and diagnostic themes.
Education • Awareness • Collaboration
Educational note: The archived presentations reflect the evidence and perspectives available at the time of recording. Research continues to evolve, and the material is intended for professional education rather than individual treatment recommendations.
